Navigation Links
NHP Reports 2009 First Quarter Results
Date:5/7/2009

e same period of 2008:

                             SELECTED FINANCIAL DATA
                    ($ in thousands, except per share amounts)


                                              Three Months Ended March 31,
                                           ---------------------------------
                                           2009     2008   $ Change % Change
                                           ----     ----   -------- --------

    Revenue                               $97,251  $85,270  $11,981     14.1%
    Income from Continuing Operations     $29,399  $22,940   $6,459     28.2%
    Net Income Attributable to NHP
     Common Stockholders                  $49,154  $35,393  $13,761     38.9%
    Net Income Attributable to NHP Common
     Stockholders Per Diluted Share         $0.47    $0.37    $0.10     27.0%
    Diluted FFO                           $61,569  $56,293   $5,276      9.4%
    Diluted FFO Per Share                   $0.57    $0.56    $0.01      1.8%
    Diluted FAD                           $61,427  $54,571   $6,856     12.6%
    Diluted FAD Per Share                   $0.57    $0.54    $0.03      5.6%

NON-GAAP FINANCIAL MEASURES

Diluted Funds From Operations ("FFO") and Diluted Funds Available for Distribution ("FAD") are non-GAAP measures that we believe are important to understanding our operations. We believe diluted FFO is an important supplemental measure of operating performance because it excludes the effects of depreciation and amortization and gains (losses) from sales of facilities (both of which are based on historical costs and which may be of limited relevance in evaluating current performance). We believe diluted FAD is an important supplemental measure of operating performance because, like diluted FFO, it excludes the effects of depreciation and amortization and gains (losses) from sales of facilities (both of which
'/>"/>

SOURCE Nationwide Health Properties, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
2. PLC Systems Reports First Quarter 2009 Results
3. Perrigo Reports Record Third Quarter
4. Symmetry Medical Reports First Quarter 2009 Financial Results
5. Orchid Cellmark Reports Improved First Quarter 2009 Financial Results
6. Labopharm Reports Results for First Quarter Fiscal 2009
7. Isis Reports Strong Financial Results and Highlights for First Quarter of 2009
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Stereotaxis Reports First Quarter 2009 Financial Results
10. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
11. The Ensign Group Reports First Quarter 2009 Earnings of $0.38 per Share; Reaffirms 2009 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... can do a lot to keep kids safe, experts say, , ... to be), youngsters are probably going to be spending less ... doing cannonballs. , It,s all fun and games -- until someone ... warn child safety experts. , Though many injuries amount to little ...
... Invited to Attend , , NEW ORLEANS, June 6 ... New Orleans for the 2009 Catholic Health Assembly, "In Our ... , The assembly, hosted by the Catholic Health Association of ... Catholic health care leaders from across the nation. They come ...
... ... Low Vision Conditions , ... Beach, CA (PRWEB) June 6, 2009 -- Enhanced Vision , America,s leading manufacturer of ... VISION 5K Run & Walk in Boston, MA this Saturday, June 7th. The unique event ...
... , - These acquisitions reinforce Genomma Lab,s presence in the cosmetics ... lotions and perfumes segments , , - Genomma Lab continues ... place in June 2008 , , ... C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), one of ...
... study found diabetes drug didn,t increase chances of heart disease, ... drug Avandia significantly raises the risk of both heart failure ... for either cardiovascular disease or death, new research has found. ... risk of death, said the authors of the much-anticipated RECORD ...
... June 5 NxStage Medical, Inc. (Nasdaq: ... today announced it has completed the closing of its ... alliance partner, Asahi Kasei Kuraray Medical. The Company used ... its entire debt obligation, including prepayment and other transaction ...
Cached Medicine News:Health News:Summer Fun Need Not Be Hazardous 2Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 2Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 3Health News:Enhanced Vision Supports America's Leading Event for Blind and Visually Impaired 2Health News:Enhanced Vision Supports America's Leading Event for Blind and Visually Impaired 3Health News:Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns 2Health News:Avandia Raises Risk of Heart Failure, Fractures 2Health News:Avandia Raises Risk of Heart Failure, Fractures 3Health News:Avandia Raises Risk of Heart Failure, Fractures 4Health News:NxStage Announces Closing of $40 Million Debt Financing with Asahi Kasei Kuraray Medical 2
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), ... its long-term extension to its open label Phase I/II study ... therapy for patients with type 1 Gaucher disease.  The data ... Gaucher Disease (EWGGD) in Cologne, Germany , and add ...
... July 1 Sagent Pharmaceuticals, Inc., a privately ... Food and Drug Administration (FDA) has approved the Company,s ... a vital anticoagulant, preventing the formation of clots and ... in surgical and dialysis settings.  According to IMS, 2009 ...
Cached Medicine Technology:Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 2Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 3Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 4Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 5Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 6FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 3FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 4
... a sterile, nonpyrogenic, viscoelastic preparation of ... weight fraction of sodium hyaluronate., ,Healon ... dissolved in physiological sodium chloride phosphate ... weight polymer is made up of ...
... System is designed to give two viscoelastic ... be used differently and sequentially to perform ... choice of the viscoelastic is based upon ... each to facilitate performance of the surgical ...
... During fiscal year 2004, Biomet ... Navigation System to the global market, ... procedures. The Acumen technology was developed ... private company based in Hollywood, Florida. ...
... in awhile, a product comes along that ... in its category. The new StealthStation TREON ... a product. Built on the phenomenal success ... surgical navigation system in the worldthe new ...
Medicine Products: